BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190722
DTEND;VALUE=DATE:20190825
DTSTAMP:20260730T000539
CREATED:20190722T192549Z
LAST-MODIFIED:20190722T192549Z
UID:21328-1563753600-1566691199@ces.b2sg.org
SUMMARY:Research Fellow
DESCRIPTION:The Beltran laboratory at Dana-Farber Cancer Institute and Harvard Medical School is focused on the study of treatment resistance in prostate cancer. We utilize a variety of molecular biology and genomic and epigenomic approaches to understand prostate cancer disease progression\, therapy resistance\, and tumor heterogeneity both in patients and in preclinical models. We are particularly focused on the emerging subset of advanced prostate cancers that lose androgen receptor dependence as a mechanism of treatment resistance\, associated with lineage plasticity and a change in clinical and pathologic characteristics towards a small cell/neuroendocrine phenotype. Current projects include: 1) Defining and validating the essential genes during neuroendocrine prostate cancer progression using genome-scale CRISPR-Cas9 screening approaches to identify novel therapeutic targets; 2) Understanding the genetic\, epigenetic\, and phenotypic changes that drive cancer progression through bulk and single cell molecular analyses of tumor biopsies and patient-derived models; 3) Elucidating the mechanism\, timing\, and cooperation of identified drivers including MYCN\, AURKA\, EZH2\, RB1\, and others; 4) Characterization and preclinical testing of novel epigenetic and immune -based therapeutic approaches and combination strategies to treat\, revert\, or prevent non-AR driven resistance. Research in the laboratory ranges from basic mechanistic investigation of cancer gene function to highly translational genomic and functional studies of patient-derived tissues from clinical trials. Team members work in a highly collaborative environment that includes laboratory investigators\, clinical investigators\, and computational biologists. We are seeking an enthusiastic\, dedicated and hardworking post-doctoral scientist to join our team. The successful candidate will have a strong interest in cancer biology and therapeutics with experience in molecular biology\, biochemistry\, genetics/genomics or biochemistry. The Beltran lab recently relocated from Weill Cornell to DFCI. While the lab’s new DFCI website is still in development\, more information on the lab’s research may be found at beltranlab.weill.cornell.edu \n\nSpecific responsibilities include: \n\nPerforming cell and molecular biology research including but not limited to 2D and 3D cell culture\, genetic manipulation through shRNA/CRISPR\, protein/RNA/DNA analyses including Western blotting\, RNA-seq\, IP-MS\, and ChIP-seq.\nLentiviral transduction techniques for ORF-overexpression experiments or RNAi and CRISPR-Cas9 knockdown/knockout experiments.\nPerforming a variety of basic cancer biology assays\, including in vitro proliferation or apoptosis assays\, drug sensitivity assays\, soft agar assays and in vivo xenograft experiments.\nWorking with a team of experimental and computational biologists to analyze and interpret sequencing data as well as gain- and loss-of-function genetic or pharmacologic screening data.\nPerforming detailed characterization and cellular mechanism of action studies of genetic or pharmacologic screening hits.\nPerforming preclinical translational studies in mouse models of cancer.\nEffectively work with research technicians and cross-functional project teams\nMaintaining accurate records\, writing reports\, and preparing/giving presentations.\n\n\n\n\nQualifications\n\n\n\n\nMD\, PhD or MD/PhD in biological sciences or equivalent\nStrong work ethic\, positive attitude and team-centered mentality\nA strong background in molecular and/or cell biology\, biochemistry\, genomics or cancer biology.\nExperience with genomics\, functional genetic screens or mouse models of cancer (xenografts\, PDXs\, GEMMs) and/or computational skills including computer programming are of interest\nExcellent oral and written communication skills.\nThe ability to perform both self-directed and guided research is required. \nMust demonstrate outstanding ability to work effectively as part of an interdisciplinary team of scientists.
URL:https://ces.b2sg.org/event/df-22jul19/
LOCATION:Dana-Farber Cancer Institute\, 450 Brookline Avenue\, Boston\, MA\, 02215\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/11/Dana-Farber.jpg
END:VEVENT
END:VCALENDAR